Julian Francis Burke
Directeur/Membre du Conseil chez The Company of Biologists Ltd.
Profil
Julian Francis Burke is currently a Director at The Company of Biologists Ltd.
and a Non-Executive Director at Solentim Ltd.
He previously worked at Genetix Group Ltd.
as an Executive Director & Scientific Director from 1993 to 2010.
Postes actifs de Julian Francis Burke
| Sociétés | Poste | Début |
|---|---|---|
The Company of Biologists Ltd.
 The Company of Biologists Ltd. Miscellaneous Commercial ServicesCommercial Services The Company of Biologists Ltd. is a not-for-profit publishing organization that supports and inspires the biological community. The non-profit company is based in Histon, UK. The British company is run by distinguished practicing scientists and exist to profit science, not shareholders. The company publishes leading peer-reviewed journals such as Development, Journal of Cell Science, and Journal of Experimental Biology. The company offers a range of resources to early-career researchers and have chosen the 'transformative' route towards Open Access. The company promotes the use of Caenorhabditis elegans to investigate ten of the 14 cancer hallmarks that define the mechanisms of cancer. | Directeur/Membre du Conseil | - |
Solentim Ltd.
 Solentim Ltd. BiotechnologyHealth Technology Part of Advanced Instruments LLC, Solentim Ltd. is a British company that specializes in workflows for antibody and cell-based therapies. The company is based in Wimborne, UK. The company's technologies enable the isolation, growth, and characterization of high-value cells, while their data-driven platform enables smarter decisions earlier in the process. The CEO of the company is Mark Truesdale. Solentim was acquired by Advanced Instruments LLC on September 30, 2021 for $333.83 million. | Directeur/Membre du Conseil | - |
Anciens postes connus de Julian Francis Burke
| Sociétés | Poste | Fin |
|---|---|---|
Genetix Group Ltd.
 Genetix Group Ltd. Medical SpecialtiesHealth Technology Genetix Group Ltd. provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis. The company operates research, pharmaceutical and biotherapeutic developments. Its product brands include ClonePix, Clone Pix FL, Clone Select Imager, Clone Fill, Cell Dispense, QP Expression, QP Display, QP Interactor, OP Evolution, Q Select, O Pix2 XT, O Pix2, MegaPix, QBot, gelPix, gloPix, Q ArrayMini, Q Array2, Q ArrayMax, aliQuot, Q Fill and Mega Pix. Genetix was founded by Mark Reid in 1991 and is headquartered in New Milton, the United Kingdom. | Directeur Technique/Scientifique/R&D | 14/01/2010 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Genetix Group Ltd.
Genetix Group Ltd. Medical SpecialtiesHealth Technology Genetix Group Ltd. provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis. The company operates research, pharmaceutical and biotherapeutic developments. Its product brands include ClonePix, Clone Pix FL, Clone Select Imager, Clone Fill, Cell Dispense, QP Expression, QP Display, QP Interactor, OP Evolution, Q Select, O Pix2 XT, O Pix2, MegaPix, QBot, gelPix, gloPix, Q ArrayMini, Q Array2, Q ArrayMax, aliQuot, Q Fill and Mega Pix. Genetix was founded by Mark Reid in 1991 and is headquartered in New Milton, the United Kingdom. | Health Technology |
The Company of Biologists Ltd.
The Company of Biologists Ltd. Miscellaneous Commercial ServicesCommercial Services The Company of Biologists Ltd. is a not-for-profit publishing organization that supports and inspires the biological community. The non-profit company is based in Histon, UK. The British company is run by distinguished practicing scientists and exist to profit science, not shareholders. The company publishes leading peer-reviewed journals such as Development, Journal of Cell Science, and Journal of Experimental Biology. The company offers a range of resources to early-career researchers and have chosen the 'transformative' route towards Open Access. The company promotes the use of Caenorhabditis elegans to investigate ten of the 14 cancer hallmarks that define the mechanisms of cancer. | Commercial Services |
Solentim Ltd.
Solentim Ltd. BiotechnologyHealth Technology Part of Advanced Instruments LLC, Solentim Ltd. is a British company that specializes in workflows for antibody and cell-based therapies. The company is based in Wimborne, UK. The company's technologies enable the isolation, growth, and characterization of high-value cells, while their data-driven platform enables smarter decisions earlier in the process. The CEO of the company is Mark Truesdale. Solentim was acquired by Advanced Instruments LLC on September 30, 2021 for $333.83 million. | Health Technology |